Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa PharmaceuticalsCentessa Pharmaceuticals(US:CNTA) GlobeNewswire News Room·2024-08-13 11:00

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 - Reportify